Therapy Gaps: Identifying New Targets in the Management of NSCLC - a podcast by ReachMD

CME credits: 0.25

Valid until: 20-05-2022

Claim your CME credit at https://reachmd.com/programs/cme/therapy-gaps-identifying-new-targets-management-nsclc/12515/

Dysregulation of MET signaling has been widely described in oncogenic processes. While all 3 types of MET dysregulation (amplification, overexpression, and gene mutations) have been documented in non-small cell lung cancer (NSCLC), MET exon 14 skipping alterations are a primary oncogenic driver in approximately 3% to 4% of these patients, often with a poor outcome. Join us as Dr. Paul Paik and Dr. Viola Zhu discuss the importance of testing patients for MET gene aberrations and their relevance in the management of NSCLC, especially as related to recently approved and emerging therapies for patients harboring a MET gene aberration.

Further episodes of ReachMD CME

Further podcasts by ReachMD

Website of ReachMD